Recent Updates
Recently added Catalysts
HRTX Positive Sentiment

Heron Therapeutics to Report Second Quarter 2025 Financial Results on Monday, August 11, 2025

Key Takeaway: Heron Therapeutics, Inc. will host a conference call on August 11, 2025, to report its second quarter financial results and discuss recent business highlights. The call will be accessible via phone and webcast, with an archive available for 60 days. The company emphasizes its commitment to improving patient care through innovative therapies.
Price reaction · baseline $1.86 (2025-07-28 close) · hit after-hours · clean, no other HRTX news in the window
day 0 close
-0.5%

Market Sentiment Analysis

POSITIVE FACTORS

  • Heron Therapeutics is actively engaging with investors through a conference call.
  • The company is focused on developing therapeutic innovations for patient care.
  • Heron's financial results and business highlights indicate ongoing growth and transparency.

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+23%
120-day peak, hindsight
Typical move
9.3%
average across 7 past catalysts
Cash runway
~56 mo
Minimal dilution risk
Lead asset
HTX-011A
Phase 2 · Postoperative Pain

Full Press Release Details

CARY, N.C.,July 28, 2025/PRNewswire/ -- Heron Therapeutics, Inc. (Nasdaq:HRTX) ("Heron" or the "Company"), a commercial-stage biotechnology company, today announced that the Company will host a conference call and live webcast onMonday, August 11, 2025, at4:30 p.m. ETto report second quarter 2025 financial results and discuss recent business highlights.
The conference call can be accessed by phone by utilizing the followingregistration linkwhich will provide participants with dial-in details. To avoid delays, we encourage participants to dial into the conference call fifteen minutes ahead of the scheduled start time. The conference call will also be available via webcast under the Investor Relations section of Heron's website atwww.herontx.com. An archive of the teleconference and webcast will also be made available on Heron's website for 60 days following the call.

About Heron Therapeutics, Inc.

Heron Therapeutics, Inc. is a commercial-stage biotechnology company focused on improving the lives of patients by developing and commercializing therapeutic innovations that improve medical care. Our advanced science, patented technologies, and innovative approach to drug discovery and development have allowed us to create and commercialize a portfolio of products that aim to advance the standard-of-care for acute care and oncology patients. For more information, visitwww.herontx.com.

Forward-looking Statements

This news release contains "forward-looking statements" as defined by the Private Securities Litigation Reform Act of 1995. Heron cautions readers that forward-looking statements are based on management's expectations and assumptions as of the date of this news release and are subject to certain risks and uncertainties that could cause actual results to differ materially. These risks and uncertainties include, but are not limited to, risks and uncertainties identified in the Company's filings with the Securities and Exchange Commission. Forward-looking statements reflect our analysis only on their stated date, and Heron takes no obligation to update or revise these statements except as may be required by law.

Investor Relations and Media Contact:

Frequently Asked Questions

When will Heron Therapeutics report its Q2 2025 results?

Heron Therapeutics will report its Q2 2025 financial results on August 11, 2025.

How can I access the conference call?

The conference call can be accessed via phone or through a live webcast on Heron's website.

What time is the conference call scheduled?

The conference call is scheduled for 4:30 p.m. ET on August 11, 2025.

Will there be an archive of the conference call?

Yes, an archive of the teleconference and webcast will be available for 60 days.

Last updated: Jul 29, 2025